Actively Recruiting
A Study of EBC-129 in Advanced Solid Tumours
Led by EDDC (Experimental Drug Development Centre), A*STAR Research Entities · Updated on 2026-02-05
98
Participants Needed
5
Research Sites
190 weeks
Total Duration
On this page
Sponsors
E
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Lead Sponsor
P
Parexel
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours
CONDITIONS
Official Title
A Study of EBC-129 in Advanced Solid Tumours
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients 18 years (US) or 21 years (Singapore) and older
- Body weight between 40 kg and 100 kg during Parts A and B, and up to 120 kg in other parts
- Have progressed locally advanced unresectable or metastatic solid tumor without effective standard treatment options or intolerant to such therapies
- Eastern Cooperative Oncology Group performance status of 2 or less for Part A, and 0-1 for Parts B, C, and D
- Adequate liver, kidney, and bone marrow function as defined by the study protocol
You will not qualify if you...
- Unable or unwilling to provide tumor tissue sample unless biopsy risk is significant
- Received investigational or anti-cancer therapy within 28 days before starting study drug
- Currently receiving any other anti-cancer therapy
- Known severe allergy to E coli-derived products, filgrastim, or peg-filgrastim
- Clinically active brain metastases
- Received prior radiation therapy
- Received prophylactic hematopoietic colony stimulating factors within 28 days before starting study drug
- Using strong P-glycoprotein inducers/inhibitors or strong CYP3A inhibitors within 14 days before first dose or restricted medications
- Pregnant or breastfeeding
- For pembrolizumab recipients: active autoimmune disease requiring systemic treatment in past 2 years, prior serious immune-related adverse events requiring permanent discontinuation, unresolved or steroid-dependent immune adverse events, history of pneumonitis/interstitial lung disease, live vaccines within 30 days, or prior Grade 2 myocarditis
- Major surgery within 28 days before starting study drug
- Active or chronic corneal or ocular conditions preventing monitoring of drug-induced keratopathy
- Active infections including HIV, Hepatitis B, or Hepatitis C
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
University of Colorado Hospital (UCH) - University of Colorado Cancer Center (UCCC) - Neuroendocrine Tumor Center
Aurora, Colorado, United States, 80045-2517
Actively Recruiting
2
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
3
National University Hospital - Medical Oncology
Singapore, South West, Singapore, 119228
Actively Recruiting
4
National Cancer Centre Singapore
Singapore, South West, Singapore, 168583
Actively Recruiting
5
Taipei Veterans General Hospital
Taipei, Taipei, Taiwan, 11217
Not Yet Recruiting
Research Team
V
Venkateshan Srirangam Prativadibhayankara, MD
CONTACT
V
Veronica Diermayr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
8
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here